Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial

BACKGROUND: In TANGO, switching to dolutegravir/lamivudine (DTG/3TC) demonstrated long-term noninferior efficacy vs continuing tenofovir alafenamide–based regimens in treatment-experienced adults with HIV-1. The phase 3 SALSA study evaluated efficacy and safety of switching to DTG/3TC compared with...

Descripción completa

Detalles Bibliográficos
Autores principales: Llibre, Josep M, Brites, Carlos, Cheng, Chien-Yu, Osiyemi, Olayemi, Galera, Carlos, Hocqueloux, Laurent, Maggiolo, Franco, Degen, Olaf, Taylor, Stephen, Blair, Elizabeth, Man, Choy, Wynne, Brian, Oyee, James, Underwood, Mark, Curtis, Lloyd, Bontempo, Gilda, van Wyk, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021070/
https://www.ncbi.nlm.nih.gov/pubmed/35235656
http://dx.doi.org/10.1093/cid/ciac130

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021070/
https://www.ncbi.nlm.nih.gov/pubmed/35235656
http://dx.doi.org/10.1093/cid/ciac130

Ejemplares similares